NewLink Genetics Corp (NLNK) Expected to Post Quarterly Sales of $2.72 Million

Equities research analysts expect that NewLink Genetics Corp (NASDAQ:NLNK) will post $2.72 million in sales for the current fiscal quarter, Zacks reports. Three analysts have made estimates for NewLink Genetics’ earnings, with the highest sales estimate coming in at $5.00 million and the lowest estimate coming in at $300,000.00. NewLink Genetics posted sales of $12.70 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 78.6%. The company is expected to announce its next earnings results on Tuesday, February 27th.

According to Zacks, analysts expect that NewLink Genetics will report full year sales of $2.72 million for the current financial year, with estimates ranging from $18.61 million to $23.60 million. For the next year, analysts expect that the business will report sales of $12.20 million per share, with estimates ranging from $1.10 million to $20.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that that provide coverage for NewLink Genetics.

NewLink Genetics (NASDAQ:NLNK) last announced its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.69) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.05. NewLink Genetics had a negative return on equity of 63.39% and a negative net margin of 229.19%.

A number of brokerages have weighed in on NLNK. Cantor Fitzgerald set a $26.00 target price on NewLink Genetics and gave the stock a “buy” rating in a research note on Monday, January 8th. BidaskClub upgraded NewLink Genetics from a “sell” rating to a “hold” rating in a research report on Friday, January 5th. Zacks Investment Research downgraded NewLink Genetics from a “buy” rating to a “hold” rating in a research report on Thursday, January 4th. Jefferies Group lowered their target price on NewLink Genetics from $26.00 to $25.00 and set a “buy” rating on the stock in a research report on Friday, November 3rd. Finally, Stifel Nicolaus lifted their target price on NewLink Genetics from $25.00 to $29.00 and gave the company a “buy” rating in a research report on Friday, November 3rd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $23.29.

Shares of NewLink Genetics (NLNK) traded up $0.32 during midday trading on Tuesday, reaching $8.88. The company’s stock had a trading volume of 272,121 shares, compared to its average volume of 954,043. The company has a market cap of $313.32, a price-to-earnings ratio of -3.64 and a beta of 1.10. NewLink Genetics has a fifty-two week low of $5.90 and a fifty-two week high of $25.17.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC lifted its position in NewLink Genetics by 241.6% during the fourth quarter. Acadian Asset Management LLC now owns 19,470 shares of the biotechnology company’s stock valued at $158,000 after purchasing an additional 13,770 shares in the last quarter. Schwab Charles Investment Management Inc. raised its holdings in NewLink Genetics by 22.8% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 100,944 shares of the biotechnology company’s stock valued at $819,000 after acquiring an additional 18,712 shares during the period. Creative Planning bought a new stake in NewLink Genetics during the fourth quarter valued at about $152,000. GSA Capital Partners LLP raised its holdings in NewLink Genetics by 653.7% during the third quarter. GSA Capital Partners LLP now owns 132,154 shares of the biotechnology company’s stock valued at $1,345,000 after acquiring an additional 114,620 shares during the period. Finally, Neuberger Berman Group LLC bought a new stake in NewLink Genetics during the third quarter valued at about $305,000. Institutional investors own 52.30% of the company’s stock.

TRADEMARK VIOLATION WARNING: “NewLink Genetics Corp (NLNK) Expected to Post Quarterly Sales of $2.72 Million” was reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another publication, it was copied illegally and republished in violation of international copyright law. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/23/newlink-genetics-corp-nlnk-expected-to-post-quarterly-sales-of-2-72-million.html.

About NewLink Genetics

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Get a free copy of the Zacks research report on NewLink Genetics (NLNK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for NewLink Genetics (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply